Cancer de l’endomètre : entre modernité et immunothérapie [Endometrial cancer in the crossroads of modernity and immunotherapy]
Fiche du document
17 mai 2023
- doi: 10.53738/REVMED.2023.19.827.944
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.827.944
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37195107
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0D5FCD1711333
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-11-17 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
B. Giacomuzzi Moore et al., « Cancer de l’endomètre : entre modernité et immunothérapie [Endometrial cancer in the crossroads of modernity and immunotherapy] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.827.944
Métriques
Partage / Export
Résumé
Frequent and with an increasing incidence in some territories, endometrial cancer is a complex disease leading to significant morbidity among affected patients. After years of research and the implementation of state-of-the-art molecular and gene assays significant breakthroughs were made. Through a better understanding of the underlying mechanisms of uterine carcinogenesis, a more precise and personalized risk stratification and the incorporation of immunotherapy, the treatment of endometrial cancer is experiencing significant improvements. This evolution, caries the genuine hope for an accurate selection of patients based on specific cancer-related characteristics, to tailor both treatment intensity and selection.